By Fineline Cube 
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced that its anti-HIV-1 drug Aitribond has received approval from the Zanzibar Food and Drug Agency (ZFDA). This marks a significant step in the global availability of this innovative triple-ingredient single-tablet compound.
Drug Composition and Mechanism
Aitribond is a combination of Aidea Pharma’s category 1 chemical drug ainuovirine, along with two nucleoside reverse transcriptase inhibitors (NRTIs) — tenofovir disoproxil fumarate (TDF) and lamivudine (3TC). This formulation provides a convenient once-daily dosing regimen, eliminating the need for additional anti-HIV medications.
Regulatory and Reimbursement Milestones
In China, Aitribond was approved by the National Medical Products Administration (NMPA) in December 2022 and was included in the national reimbursement drug list in 2023. This approval addresses a gap in domestic innovation for oral single-ingredient compound preparations in the field of HIV-1 treatment.
Patient Benefits
Aitribond significantly reduces the medication burden for patients by requiring only one tablet per day. This convenience helps improve patient compliance, enhance therapeutic outcomes, and reduce the occurrence of drug resistance.-Fineline Info & Tech